SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors react to a significant earnings beat and raised full-year guidance, with the community highlighting a return to institutional accumulation. Traders are actively debating the sustainability of this price momentum and monitoring the stock for a potential breakout toward higher levels as sentiment shifts from defensive to expansionary.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as the eVTOL leader following successful New York City demonstration flights, though the stock faces intense volatility from retail sentiment and short-selling pressure. Investors are actively debating the company's long-term commercial potential against ongoing concerns regarding high cash burn and the broader market impact on speculative tech stocks.

One & One Green Technologies, Inc. engages in the recycling, production, and trading of recycled scrap metals. Its products include copper alloy ingot, recycled aluminum, recycled tin, recycled zinc, recycled iron, and plastic beads. The company was founded on April 17, 2024 and is headquartered in Bulacan, Philippines.

One and one Green Technologies. Inc - Ordinary Shares - Class A

One and One Green Technologies Inc

One and One Green Technologies is seeing significant investor attention following a volatile NASDAQ debut, with the community focused on its low float and the strategic value of its rare hazardous waste import licenses in the Philippines. Traders are closely monitoring the stock for potential short-squeeze dynamics and follow-through momentum as the company expands its presence in global metal recycling markets.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is experiencing extreme volatility following a massive, news-free price surge that triggered widespread debate over potential pump-and-dump mechanics. While some traders are celebrating quick gains and speculative momentum, others are warning of a sharp reversal, pointing to the lack of a clear catalyst and the stock's history as a low-float, highly unpredictable mover.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending as investors react to a polarizing earnings report that featured record profits and strong user growth but fell slightly short of subscriber guidance. The community remains deeply divided, with some traders viewing the pullback as a buying opportunity given the company's improved margins and potential for future price hikes, while others express frustration over subscription costs and fear a deeper valuation reset.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is experiencing significant volatility as investors weigh strong earnings beats and raised full-year guidance against high growth expectations in the AI infrastructure sector. While the community remains divided between those identifying a 'buy the dip' opportunity based on fundamentals and those concerned about stretched valuations, the stock continues to be a battleground for momentum traders reacting to sector-wide shifts.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus shares are experiencing extreme volatility following a quarterly earnings report that missed expectations and triggered a sharp sell-off, prompting intense community debate over whether the drop represents a structural breakdown or a buying opportunity. While some investors are bracing for further downside, others are pointing to the company's strong cash position and role in the AI infrastructure cycle as reasons to accumulate shares during the price reset.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is capturing intense investor interest as the stock experiences high-volume, parabolic moves driven by speculation surrounding a potential buyout and excitement over its late-stage biotech pipeline. The community is actively discussing the companys strong institutional backing and tight effective float, with many debating the impact of upcoming conference presentations and the possibility of a strategic partnership or acquisition.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca (ERAS) is facing intense volatility and a sharp sell-off following the disclosure of a patient death in its ERAS-0015 Phase 1 trial, which some investors fear could trigger an FDA clinical hold. The community remains heavily divided, with critics alleging the company obfuscated safety risks in an 8-K filing while pushing counterfeit-labeled data, while proponents argue the reaction is an overblown opportunity to buy the dip in a company with a strong cash position and best-in-class potential.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

BridgeBio Pharma is trending as investors monitor ongoing patent litigation involving Pfizers tafamidis, which market participants view as a potential clearing event that could reduce competitive pressure on BridgeBio's rival heart drug, Attruby. The community is actively discussing the stock's long-term growth prospects, upcoming clinical trial readouts, and the company's potential as an acquisition target for large pharmaceutical firms.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


1gomfree

1gom